Clinical Practice Guidelines for Pleural Effusion and Bronchoalveolar Lavage Fluid-Based Circulating Tumor DNA Testing in Lung Cancer
Doctors can now test fluid samples from around the lungs for cancer DNA, offering new ways to monitor lung cancer without invasive procedures.
BACKGROUND: Pleural effusion (PE) and bronchoalveolar lavage fluid (BALF) are increasingly investigated as alternative sources of circulating tumor DNA (ctDNA) for lung cancer molecular testing. CONCLUSIONS: These consensus-based recommendations practically guide the implementation, validation, reporting, and interpretation of PE/BALF-based ctDNA testing in lung cancer, while highlighting the need for further matrix-specific evidence, particularly for BALF.
What the study was
- Study design
- Journal Article
- Population
- BACKGROUND: Pleural effusion (PE) and bronchoalveolar lavage fluid (BALF) are increasingly investiga
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Annals of laboratory medicine
Why it surfaced
Primary method is liquid biopsy/ctDNA/cfDNA for cancer detection; moderate relevance to watchlist
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.